Skip to main content
Journal cover image

The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration.

Publication ,  Journal Article
Talks, J; Daien, V; Finger, RP; Eldem, B; Sakamoto, T; Cardillo, JA; Mitchell, P; Wong, TY; Korobelnik, J-F
Published in: Surv Ophthalmol
2019

Randomized controlled trials are the gold standard in medical research, providing evidence of the efficacy of a treatment in well-defined patient populations. By contrast, real-world studies explore the effectiveness of treatments in routine clinical practice, often with diverse patient populations. Although both randomized controlled trials and real-world studies contribute to the understanding of the benefits and risks of therapies, they generate different types of data and serve complementary purposes. Real-world studies evaluating the management of neovascular age-related macular degeneration have shown that visual outcomes achieved with anti-vascular endothelial growth factor in clinical practice often differ from those derived from clinical trials, highlighting the importance of assessing such outcomes in real-world studies. Benefits include finding variations in treatment provision, leading to: service improvements; the understanding of the need for continued and higher than previously provided treatment frequency; and new treatment regimens such as treat-and-extend. There is potential for the scope of real-world studies to be expanded to include other patient outcomes, such as quality of life, thus providing decision-makers with additional information to complement the data collected in randomized controlled trials. Physicians, patients, and regulators stand to gain much from further development and the conduct of real-world studies. We provide an overview of the importance of real-world evidence in the management of neovascular age-related macular degeneration with anti-vascular endothelial growth factor therapy, describe sources of real-world evidence, and assess the relative strengths and limitations of randomized controlled trials and real-world studies.

Duke Scholars

Published In

Surv Ophthalmol

DOI

EISSN

1879-3304

Publication Date

2019

Volume

64

Issue

5

Start / End Page

707 / 719

Location

United States

Related Subject Headings

  • Wet Macular Degeneration
  • Visual Acuity
  • Vascular Endothelial Growth Factor A
  • Ranibizumab
  • Quality of Life
  • Ophthalmology & Optometry
  • Intravitreal Injections
  • Humans
  • Angiogenesis Inhibitors
  • 3212 Ophthalmology and optometry
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Talks, J., Daien, V., Finger, R. P., Eldem, B., Sakamoto, T., Cardillo, J. A., … Korobelnik, J.-F. (2019). The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Surv Ophthalmol, 64(5), 707–719. https://doi.org/10.1016/j.survophthal.2019.02.008
Talks, James, Vincent Daien, Robert P. Finger, Bora Eldem, Taiji Sakamoto, José Augusto Cardillo, Paul Mitchell, Tien Yin Wong, and Jean-François Korobelnik. “The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration.Surv Ophthalmol 64, no. 5 (2019): 707–19. https://doi.org/10.1016/j.survophthal.2019.02.008.
Talks J, Daien V, Finger RP, Eldem B, Sakamoto T, Cardillo JA, et al. The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Surv Ophthalmol. 2019;64(5):707–19.
Talks, James, et al. “The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration.Surv Ophthalmol, vol. 64, no. 5, 2019, pp. 707–19. Pubmed, doi:10.1016/j.survophthal.2019.02.008.
Talks J, Daien V, Finger RP, Eldem B, Sakamoto T, Cardillo JA, Mitchell P, Wong TY, Korobelnik J-F. The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Surv Ophthalmol. 2019;64(5):707–719.
Journal cover image

Published In

Surv Ophthalmol

DOI

EISSN

1879-3304

Publication Date

2019

Volume

64

Issue

5

Start / End Page

707 / 719

Location

United States

Related Subject Headings

  • Wet Macular Degeneration
  • Visual Acuity
  • Vascular Endothelial Growth Factor A
  • Ranibizumab
  • Quality of Life
  • Ophthalmology & Optometry
  • Intravitreal Injections
  • Humans
  • Angiogenesis Inhibitors
  • 3212 Ophthalmology and optometry